Literature DB >> 25628939

Antitumor effects of WNT2B silencing in GLUT1 overexpressing cisplatin resistant head and neck squamous cell carcinoma.

Sheng-Jiao Li1, Xiao-Ning Yang2, Han-Yu Qian1.   

Abstract

OBJECTIVES: The increased rate of glucose uptake necessary to support the growth of tumor cells is mediated by glucose transporters, and glucose transporter 1 (GLUT1) is overexpressed in several types of cancer in correlation with poor prognosis. And WNT2B overexpression is thought to be involved in tumor progression. Here, we investigated the effects of WNT2B in GLUT1 overexpressing cisplatin resistant head and neck squamous cell carcinoma (HNSCC) in vitro and in vivo.
MATERIALS AND METHODS: We generated GLUT1 overexpressing cisplatin resistant CAL27 and SCC25 oral cancer cells. Lentiviral mediated knock-down of WNT2B was performed in CAL27 and SCC25. QRT-PCR and Western blot analysis were used to detect the mRNA and protein expression of GLUT1, WNT2B, Cyclin D1 and β-catenin. Cell viability was assessed by MTT analysis. Colony formation assay was performed by staining with 0.5% crystal violet. The role of WNT2B in HNSCC was examined in vivo through the generation of a CAL27 (or cisplatin resistant CAL27 or cisplatin resistant CAL27 with WNT2B knock-down) nude mice xenograft model of HNSCC.
RESULTS: Knock-down of WNT2B in decreased cell viability and colony formation in cisplatin resistant CAL27 and SCC25 in association with the downregulation of GLUT1, cyclin D1 and β-catenin. In a cisplatin resistant CAL27 mouse xenograft model, shRNA mediated silencing of WNT2B increased survival and decreased tumor growth in correlation with the downregulation of GLUT1, cyclin D1 and β-catenin.
CONCLUSION: WNT2B plays a role in tumorigenesis and chemotherapy resistance in oral cancer and provide a potential therapeutic target for the treatment of patients with HNSCC.

Entities:  

Keywords:  GLUT1; WNT2B; cisplatin; head and neck squamous cell carcinoma

Year:  2014        PMID: 25628939      PMCID: PMC4300709     

Source DB:  PubMed          Journal:  Am J Cancer Res        ISSN: 2156-6976            Impact factor:   6.166


  24 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

2.  The effects of GLUT1 on the survival of head and neck squamous cell carcinoma.

Authors:  Shengjiao Li; Xiaoning Yang; Peng Wang; Xing Ran
Journal:  Cell Physiol Biochem       Date:  2013-09-10

Review 3.  The complex world of WNT receptor signalling.

Authors:  Christof Niehrs
Journal:  Nat Rev Mol Cell Biol       Date:  2012-11-15       Impact factor: 94.444

4.  Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells.

Authors:  O Tetsu; F McCormick
Journal:  Nature       Date:  1999-04-01       Impact factor: 49.962

5.  Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC-/- colon carcinoma.

Authors:  V Korinek; N Barker; P J Morin; D van Wichen; R de Weger; K W Kinzler; B Vogelstein; H Clevers
Journal:  Science       Date:  1997-03-21       Impact factor: 47.728

Review 6.  Glucose transporters in the 21st Century.

Authors:  Bernard Thorens; Mike Mueckler
Journal:  Am J Physiol Endocrinol Metab       Date:  2009-12-15       Impact factor: 4.310

7.  Cross-talk between HER2 and MED1 regulates tamoxifen resistance of human breast cancer cells.

Authors:  Jiajun Cui; Katherine Germer; Tianying Wu; Jiang Wang; Jia Luo; Shao-chun Wang; Qianben Wang; Xiaoting Zhang
Journal:  Cancer Res       Date:  2012-09-10       Impact factor: 12.701

8.  The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway.

Authors:  M Shtutman; J Zhurinsky; I Simcha; C Albanese; M D'Amico; R Pestell; A Ben-Ze'ev
Journal:  Proc Natl Acad Sci U S A       Date:  1999-05-11       Impact factor: 11.205

Review 9.  Expression of glucose transporters in cancers.

Authors:  Leszek Szablewski
Journal:  Biochim Biophys Acta       Date:  2012-12-21

10.  Overexpression of glucose transporter-1 (GLUT-1) predicts poor prognosis in epithelial ovarian cancer.

Authors:  Hanbyoul Cho; You Sun Lee; Julie Kim; Joon-Yong Chung; Jae-Hoon Kim
Journal:  Cancer Invest       Date:  2013-11       Impact factor: 2.176

View more
  15 in total

1.  Genetic Variants in WNT2B and BTRC Predict Melanoma Survival.

Authors:  Qiong Shi; Hongliang Liu; Peng Han; Chunying Li; Yanru Wang; Wenting Wu; Dakai Zhu; Christopher I Amos; Shenying Fang; Jeffrey E Lee; Jiali Han; Qingyi Wei
Journal:  J Invest Dermatol       Date:  2017-05-10       Impact factor: 8.551

2.  Construction and application of a lung cancer stem cell model: antitumor drug screening and molecular mechanism of the inhibitory effects of sanguinarine.

Authors:  Jia Yang; Zhihong Fang; Jianchun Wu; Xiaoling Yin; Yuan Fang; Fanchen Zhao; Shiguo Zhu; Yan Li
Journal:  Tumour Biol       Date:  2016-08-02

3.  PAX5 gene as a novel methylation marker that predicts both clinical outcome and cisplatin sensitivity in esophageal squamous cell carcinoma.

Authors:  Keisuke Kurimoto; Masamichi Hayashi; Rafael Guerrero-Preston; Masahiko Koike; Mitsuro Kanda; Sho Hirabayashi; Hiroshi Tanabe; Nao Takano; Naoki Iwata; Yukiko Niwa; Hideki Takami; Daisuke Kobayashi; Chie Tanaka; Suguru Yamada; Goro Nakayama; Hiroyuki Sugimoto; Tsutomu Fujii; Michitaka Fujiwara; Yasuhiro Kodera
Journal:  Epigenetics       Date:  2017-11-27       Impact factor: 4.528

4.  Glucose transporter 4 promotes head and neck squamous cell carcinoma metastasis through the TRIM24-DDX58 axis.

Authors:  Yu-Chan Chang; Li-Hsing Chi; Wei-Ming Chang; Chia-Yi Su; Yuang-Feng Lin; Chi-Long Chen; Ming-Huang Chen; Peter Mu-Hsin Chang; Alex T H Wu; Michael Hsiao
Journal:  J Hematol Oncol       Date:  2017-01-07       Impact factor: 17.388

5.  Molecular genetics and targeted therapy of WNT-related human diseases (Review).

Authors:  Masuko Katoh; Masaru Katoh
Journal:  Int J Mol Med       Date:  2017-07-19       Impact factor: 4.101

6.  miR-185-3p regulates the invasion and metastasis of nasopharyngeal carcinoma by targeting WNT2B in vitro.

Authors:  Chao Liu; Guo Li; Shuling Ren; Zhongwu Su; Yunyun Wang; Yongquan Tian; Yong Liu; Yuanzheng Qiu
Journal:  Oncol Lett       Date:  2017-02-24       Impact factor: 2.967

7.  miR-324-3p suppresses migration and invasion by targeting WNT2B in nasopharyngeal carcinoma.

Authors:  Yong Liu; Yuanzheng Qiu; Chao Liu; Guo Li; Nianting Yang; Zhongwu Su; Shuiting Zhang; Tengbo Deng; Shuling Ren; Shanhong Lu; Yongquan Tian
Journal:  Cancer Cell Int       Date:  2017-01-03       Impact factor: 5.722

8.  MicroRNA‑137 suppresses the proliferation, migration and invasion of cholangiocarcinoma cells by targeting WNT2B.

Authors:  Tengxiang Chen; Shan Lei; Zhirui Zeng; Shutao Pan; Jinjuan Zhang; Yan Xue; Yuanmei Sun; Jinzhi Lan; Su Xu; Dahua Mao; Bing Guo
Journal:  Int J Mol Med       Date:  2020-01-23       Impact factor: 4.101

Review 9.  The Significance of the Dysregulation of Canonical Wnt Signaling in Head and Neck Squamous Cell Carcinomas.

Authors:  Jarosław Paluszczak
Journal:  Cells       Date:  2020-03-15       Impact factor: 6.600

10.  The Combination of MK-2206 and WZB117 Exerts a Synergistic Cytotoxic Effect Against Breast Cancer Cells.

Authors:  Yu-Liang Li; Hao-Cheng Weng; Jui-Ling Hsu; Shu-Wha Lin; Jih-Hwa Guh; Lih-Ching Hsu
Journal:  Front Pharmacol       Date:  2019-11-06       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.